News

Cherry Blossoms at ISA
Report from the 2018 International Symposium on Amyloidosis
This past month, ARC CEO Isabelle Lousada headed to the International Symposium on Amyloidosis (ISA) in Kumamoto, Japan. (more…)
Read More
Clinical Resources APP
ARC Launches Version Two of Powerful Amyloidosis Diagnostic App
A recent ARC survey showed that patients typically see four or more physicians before getting accurately diagnosed, and often those who were misdiagnosed were receiving treatment for their misdiagnosis. The Clinical Resources App was developed to provide healthcare professionals with...
Read More
Research
Groundbreaking News for ATTR Cardiac Amyloidosis Community
Yesterday was a big milestone for the ATTR amyloidosis community. Pfizer announced the results from their phase III ATTR-ACT study of tafamidis for patients with cardiac ATTR amyloidosis. The results demonstrated a statistically significant reduction in the numbers of deaths...
Read More
Rare Disease Week
2018 Rare Disease Week on Capitol Hill
Every year around Rare Disease Day (February 28th), The EveryLife Foundation hosts Rare Disease Week on Capitol Hill. The event aims to bring together the rare disease community to educate them federal legislative issues and give them the chance to...
Read More
Pfizer Research
Pfizer’s 2018 Global ASPIRE TTR Amyloidosis Competitive Grants Program
Pfizer is pleased to announce the 2018 Global ASPIRE Transthyretin (TTR) Amyloidosis Competitive Research Grant Awards for Junior Investigators. The Global ASPIRE TTR Amyloidosis program underscores Pfizer’s commitment to supporting investigators with an interest in advancing their academic research in...
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization